167 related articles for article (PubMed ID: 25724312)
1. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement.
Taneja S; Shilpi S; Khatri K
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):978-84. PubMed ID: 25724312
[TBL] [Abstract][Full Text] [Related]
2. Design and characterization of loratadine nanosuspension prepared by ultrasonic-assisted precipitation.
Alshweiat A; Katona G; Csóka I; Ambrus R
Eur J Pharm Sci; 2018 Sep; 122():94-104. PubMed ID: 29908301
[TBL] [Abstract][Full Text] [Related]
3. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation.
Patel GV; Patel VB; Pathak A; Rajput SJ
Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution.
Sartori GJ; Prado LD; Rocha HVA
AAPS PharmSciTech; 2017 Nov; 18(8):3011-3020. PubMed ID: 28493004
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
6. Fabrication and characterization of glimepiride nanosuspension by ultrasonication-assisted precipitation for improvement of oral bioavailability and in vitro α-glucosidase inhibition.
Rahim H; Sadiq A; Khan S; Amin F; Ullah R; Shahat AA; Mahmood HM
Int J Nanomedicine; 2019; 14():6287-6296. PubMed ID: 31496686
[TBL] [Abstract][Full Text] [Related]
7. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
Sahu BP; Das MK
Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
9. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
Rao MR; Bajaj A
Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
[TBL] [Abstract][Full Text] [Related]
10. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability.
Xia D; Quan P; Piao H; Piao H; Sun S; Yin Y; Cui F
Eur J Pharm Sci; 2010 Jul; 40(4):325-34. PubMed ID: 20417274
[TBL] [Abstract][Full Text] [Related]
11. Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations.
Mishra B; Sahoo J; Dixit PK
Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():62-9. PubMed ID: 27040196
[TBL] [Abstract][Full Text] [Related]
12. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
13. Formulation and development of bicontinuous nanostructured liquid crystalline particles of efavirenz.
Avachat AM; Parpani SS
Colloids Surf B Biointerfaces; 2015 Feb; 126():87-97. PubMed ID: 25543986
[TBL] [Abstract][Full Text] [Related]
14. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
[TBL] [Abstract][Full Text] [Related]
15. Formulation of dried lignans nanosuspension with high redispersibility to enhance stability, dissolution, and oral bioavailability.
Shen G; Cheng L; Wang LQ; Zhang LH; Shen BD; Liao WB; Li JJ; Zheng J; Xu R; Yuan HL
Chin J Nat Med; 2016 Oct; 14(10):757-768. PubMed ID: 28236405
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
[TBL] [Abstract][Full Text] [Related]
17. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Approach to the Development of Cilostazol Nanosuspension by Liquid Antisolvent Precipitation (LASP) and Its Combination with Ultrasound.
Jakubowska E; Milanowski B; Lulek J
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830298
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz dissolution enhancement III: Colloid milling, pharmacokinetics and electronic tongue evaluation.
Hoffmeister CR; Fandaruff C; da Costa MA; Cabral LM; Pitta LR; Bilatto SE; Prado LD; Corrêa DS; Tasso L; Silva MA; Rocha HV
Eur J Pharm Sci; 2017 Mar; 99():310-317. PubMed ID: 28042101
[TBL] [Abstract][Full Text] [Related]
20. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
